Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success.
Michael J RybakKyle C MolinaBeatriz Da SilvaScott W MuellerLaura DamioliMartin KršákMatthew A MillerDouglas N FishPublished in: Open forum infectious diseases (2022)
Tedizolid has activity against Gram-positive pathogens as well as Mycobacterium spp and Nocardia spp. Real-world evidence supporting long-term tolerability and clinical success of tedizolid is lacking. Prolonged tedizolid therapy (median, 188 days; interquartile range, 62-493 days) appeared to be well tolerated in 37 patients (8.1% experienced adverse effect leading to discontinuation). Clinical success was 81.3% in those evaluated.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- open label
- gram negative
- mycobacterium tuberculosis
- chronic kidney disease
- randomized controlled trial
- prognostic factors
- peritoneal dialysis
- multidrug resistant
- patient reported outcomes
- cell therapy
- double blind
- electronic health record
- replacement therapy
- patient reported